Bruker Daltonics Introduces Next Level of ClinProt Biomarker Discovery, Identification and Validation Solution at ASMS 2005
06 June 2005 - 9:00PM
Business Wire
Bruker Daltonics Inc. -- New ClinProt Beads for Large Proteins,
Glycomics and Antigen-Specific Analysis Combine with New Releases
of Advanced Biomarker Analysis Software Tools Bruker Daltonics Inc.
today announces the introduction of the next level of its leading
ClinProt(TM) solution for advanced biomarker discovery,
identification and validation in clinical proteomics. The extensive
ClinProt portfolio of magnetic beads for sample pre-fractionation
has now been further expanded with novel capabilities to address 1)
biomarker analysis of large proteins, 2) targeted glyco-protein
analysis, and 3) antigen-specific enrichment of selected biomarker
molecules, combined with high-performance MALDI-TOF read-out. New
ClinProt 'Large-Protein Beads' are designed to overcome previous
limitations of biomarker discovery to peptide and small proteins,
and to exploit the full mass range of up to several 100 kDaltons
supported by Bruker Daltonics' cutting-edge MALDI-TOF mass
spectrometers. These novel Large-Protein Beads are complemented by
a new DHAP matrix product, which is optimized for high molecular
weight proteins. In addition, new ClinProt 'Glyco-Beads' bridge the
gap between clinical proteomics and the important field of
glycomics. The unique Glyco-Beads offer multiple methods for
glyco-protein enrichment, including both chemical capture or
lectin-capture strategies. After glyco-protein enrichment, the
ClinProt solution now offers multiple glycomics workflows: for
example, profiling of all glycosylated peptides or proteins, or of
selected glycan-structures can be very informative in cancer
research, as many cancer cells show altered glycans on their
surface. In-depth structural analysis and identification of
specific glyco-proteins can then be accomplished using the
Company's well-established Proteineer(TM) solution for expression
proteomics, involving MALDI-TOF/TOF and/or LC-ESI-MS/MS workflows.
Finally, novel ClinProt 'Antibody-Capture Beads' allow the specific
enrichment of different protein groups with the same antigen
specificity or even of specific proteins, thus giving access to
low-abundance proteins in plasma. Enriching specific proteins via
coupling of customer-selected antibodies can give the specificity
of an immunoassay, combined with the confidence of a mass
spectrometry read-out. This allows scientists to see all proteins
bound to an antibody at once, and to distinguish the specific
protein from other isoforms, or from undesired cross-contamination,
thereby considerably increasing the confidence in any
antibody-based assay. The new ClinProt bead products are
complemented by the new, advanced ClinProTools(TM) 2.0
bioinformatics package for streamlined data interpretation.
ClinProTools 2.0 combines intuitive data visualization with
sophisticated pattern recognition algorithms for the determination
of predictive biomarker panels. Spectra not reaching the desired
quality standard can be excluded from the analysis in the graphical
user interface. The new proprietary QuickClassifier(TM) algorithm
circumvents the common problem of model generation being extremely
time-consuming. The QuickClassifier provides a classification
result in a few seconds, even for large data sets. This is further
complemented by a new multi-class Support Vector Machine (mSVM) for
high-end classifications. Multiple sample classes, for example
originating from different control groups or from staging of a
disease, are supported by the algorithms and likewise by the
visualization tools. A correlation matrix gives an overview of all
positively or negatively correlated peaks, even if they have not
been selected for a predictive pattern. This gives an optimal
overview of co-expressed signals in a set of profiling samples. In
addition, newly introduced ProfileAnalysis(TM) 1.0 software further
expands the use of electrospray ionization (ESI) time-of-flight
(TOF) mass spectrometry for clinical research and pharmaceutical
development applications, using Bruker Daltonics' micrOTOF(TM)
ESI-TOF systems. ProfileAnalysis software is well-suited for small
molecule profiling of complex biological fluids, e.g. urine. The
pattern recognition process is supported by principle component
analysis, and optimized visualization tools support the researcher
during the application of these sophisticated mathematical
approaches. Professor Dr. Thiery, Head of the Institute for
Clinical Chemistry and Laboratory Medicine in Leipzig, Germany,
commented on the new ClinProt products: "In our laboratory, the
ClinProt system has recently been shown to overcome reproducibility
problems which were reported for chip-based pre-fractionation
techniques. MALDI-TOF mass spectrometry-based profile analysis in
our hands has proved to be a promising tool for future routine
applications in the clinical laboratory. Our recently published
standard operating procedures (Baumann et al., Clinical Chemistry
2005; 51: 973-980) for standardized sample preparation give every
researcher access to proven pre-fractionation techniques when
starting research in clinical proteomics." Frank Laukien, Ph.D.,
President and CEO of Bruker Daltonics, stated: "The introduction of
our next level of ClinProt sample preparation beads and analysis
software drives biomarker analysis one step further, as it gives
access to novel applications and important assays that previously
could not be addressed efficiently. Moreover, our next-generation
ClinProt and Proteineer solutions now also are applicable to new
fields like glyco-biology, which is expected to have significant
impact in cancer research." The next-level tools in our ClinProt
solution will be presented in scientific contributions from Bruker
Daltonics during the 53rd ASMS conference on Mass Spectrometry in
San Antonio, Texas this week. ABOUT BRUKER BIOSCIENCES (NASDAQ:
BRKR) Bruker BioSciences Corporation, headquartered in Billerica,
Massachusetts, is the publicly traded parent company of Bruker
Daltonics Inc. and Bruker AXS Inc. Bruker AXS is a leading
developer and provider of life science and advanced materials
research tools based on x-ray technology. Bruker Daltonics is a
leading developer and provider of innovative life science tools
based on mass spectrometry. Bruker Daltonics also offers a broad
line of nuclear, biological and chemical (NBC) detection systems
for homeland security. For more information:
www.bruker-biosciences.com CAUTIONARY STATEMENT Any statements
contained in this press release that do not describe historical
facts may constitute forward-looking statements as that term is
defined in the Private Securities Litigation Reform Act of 1995.
Any forward-looking statements contained herein are based on
current expectations, but are subject to a number of risks and
uncertainties. The factors that could cause actual future results
to differ materially from current expectations include, but are not
limited to, risks and uncertainties relating to the Company's
reorganization strategies, integration risks, failure of
conditions, technological approaches, product development, market
acceptance, cost and pricing of the Company's products, changes in
governmental regulations, capital spending and government funding
policies, FDA and other regulatory approvals to the extent
applicable, competition, the intellectual property of others,
patent protection and litigation. These and other factors are
identified and described in more detail in our filings with the
SEC, including, without limitation, our annual report on Form 10-K
for the year ended December 31, 2004, our most recent quarterly
reports on Form 10-Q and our current reports on Form 8-K. We
disclaim any intent or obligation to update these forward-looking
statements.
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024